Project Grant R44AI152665

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...

The National Institutes of Health's National Institute of General Medical Sciences awarded Oragenics, Inc. a $769,962 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to support computer-aided design of novel lantibiotics with improved antibiotic properties from August 1, 2021 to July 31, 2022. Specifically, the awardee will investigate the molecular interaction between the lantibiotic mutacin 1140 and its target in silico to rank analogs, synthesize and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...

The National Institute of General Medical Sciences (NIGMS) awarded a $405,015 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to the Inter American University of Puerto Rico, Inc. (Metropolitan Campus) to investigate the mechanism of action of antibacterial synthetic unsaturated fatty acids (UFAs) against methicillin-resistant Staphylococcus aureus (MRSA). The key objectives of this 3-year project are to determine if UFAs such as 2-hexadecynoic acid...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...

Federal Project Grant Award Summary Microbiotix, Inc. received a $299,946 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by the Mucorales fungal order, a World Health...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $299,163 to Phase Genomics Inc. for a proof-of-concept study to develop a novel antimicrobial approach using mRNA-based delivery of bacteriophage-derived endolysin proteins. The project aims to evaluate whether self-replicating mRNA (repRNA) can successfully express an endolysin targeting vancomycin-resistant Enterococcus faecium (VRE), and...